Impact of Microvascular Inflammation on Kidney Allograft Outcome
NCT Number: NCT06496269
Status: COMPLETED
Study Type: OBSERVATIONAL
Conditions: Transplant;Failure,Kidney|Kidney Transplant Rejection
Interventions: OTHER: No intervention
Sponsor: Paris Translational Research Center for Organ Transplantation
Sex: ALL
Age: CHILD, ADULT, OLDER_ADULT
Enrollment: 6000
Study Design: Observational Model: |Time Perspective: p
Start Date: 2023-01-01
Completion Date: 2023-12-31
Locations: Pediatric Nephrology, UCLA Mattel Children's Hospital, Los Angeles, California, 90095, United States|Division of Pediatric Nephrology, Children's Pediatric Institute, Atlanta, Georgia, 30329, United States|Division of Pediatric Nephrology, Children's Mercy Hospital, Kansas City, Missouri, 64108, United States|Acute Dialysis Units, Pediatric Kidney Transplant, Charleston, South Carolina, 29425, United States|Division of Pediatric Nephrology and Hypertension, Le Bonheur Children's Hospital, Memphis, Tennessee, 38103, United States|Department of Pediatrics, Seattle Children's Hospital, Seattle, Washington, 98105, United States|Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, 53705, United States|Bordeaux University Hospital, Department of Nephrology, Transplantation, Dialysis and Apheresis, Bordeaux, France|Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Lyon, France|Department of Nephrology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France|Nantes University Hospital, Department of Nephrology, Nantes, France|Division of Pediatric Nephrology, Necker Hospital, AP-HP, Paris, France|Division of Pediatric Nephrology, Robert Debré Hospital, AP-HP, Paris, France|Kidney Transplant Department, Necker Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France|Kidney Transplant Department, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France|Department of Nephrology-Dialysis-Transplantation, Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Department of Nephrology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Berlin Institute of Health, Berlin, Germany|Department of Nephrology and Kidney Transplantation, Vall d'Hebrón University Hospital, Barcelona, Spain|Division of Abdominal and Transplantation Surgery, Department of Surgery, Geneva University Hospitals,, Geneva, Switzerland

Summary:
Graft microvascular inflammation poses a significant challenge to successful kidney transplantation due to its heterogeneous clinical presentation. There is a critical need to unravel the clinical significance of newly defined allograft microvascular inflammation phenotypes in the Banff 2022 classification and assess the implications of these new phenotypes on kidney transplant precision diagnostics and patient risk stratification.

Primary Outcome Measures: Microvascular inflammation-related diagnoses according to the Banff 2022 Classification, March 2004 to December 2023|Kidney allograft loss, March 2004 to December 2023
Secondary Outcome Measures: Transplant glomerulopathy, March 2004 to December 2023|(Recurrent) antibody-mediated rejection episode, March 2004 to December 2023